FEVER is an investigator-designed, prospective, multicentre,double-bind, randomized,
placebo-controlled,parallel-group trial. The primary objective is to compare the long-term
effects on the incidence of fatal and non-fatal stroke (and secondarily of other
cardiovascular events) of administering a small dose of the calcium antagonist felodipine (5
mg once a day) or of a placebo, in hypertensive patients whose blood pressure had
preliminarily been reduced by administering a low-dose diuretic (hydrochlorothiazide,12.5 mg
once a day) to be continued in association with felodipine or placebo, throughout the trial.
Phase:
N/A
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
Beijing Hypertension League Insititute Shanxi Kangbao Pharmaceutical company